| Ytd | 210.88% | |
| 1y | 202.00% |
| Open | Prev Close | 21.14 | Low | High | Mkt Cap | 172.09M | |||
| Vol | 0.00 | Avg Vol | 77.19K | EPS | -4.06 | P/E | -5.21 | Forward P/E | -6.64 |
| Beta | 0.53 | Short Ratio | 0.83 | Inst. Own | 42.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-04 | 50-d Avg | 17.68 | 200-d Avg | 12.18 | 1yr Est | 3.10 |
BDSX News
LOUISVILLE, Colo., July 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagno
Shares of Biodesix, Inc. (NASDAQ: BDSX - Get Free Report) have received an average rating of "Modera
Roth Capital analyst Max Masucci initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating a
Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend
Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so
Top Wall Street analysts changed outlook on top names. Find all rating changes on Benzinga's ana
BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth
The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. Whil
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnos
Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals
The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. Whil
Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript
Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus E
Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in
LOUISVILLE, Colo., April 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagn
Biodesix (NASDAQ: BDSX - Get Free Report) and Bausch + Lomb (NYSE: BLCO - Get Free Report) are both
Employee-Driven, Prestigious National Recognition for the Consistently High-Performing Biodesix Cult
Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitori
A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test's consistent cli
The mean of analysts' price targets for Biodesix (BDSX) points to an 86.5% upside in the stock. Whil
Here is how Biodesix, Inc. (BDSX) and Coherus Oncology (CHRS) have performed compared to their secto
Biodesix, Inc. (BDSX) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
On Friday morning, 446 companies hit new 52-week lows.
Companies Reporting Before The Bell • Great Elm Capital (NASDAQ:GECC) is expected to report earn
On Monday, 147 stocks hit new 52-week lows.
On Thursday, 112 stocks made new 52-week lows.
Gainers